Atika Capital Management LLC Invests $5.25 Million in uniQure N.V. $QURE

Atika Capital Management LLC acquired a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 90,000 shares of the biotechnology company’s stock, valued at approximately $5,253,000. Atika Capital Management LLC owned approximately 0.16% of uniQure at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Private Trust Co. NA acquired a new stake in uniQure during the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp lifted its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of uniQure by 358.0% in the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares during the period. Knott David M Jr bought a new stake in shares of uniQure during the third quarter worth $117,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of uniQure during the second quarter worth $151,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on QURE. Stifel Nicolaus set a $14.00 price objective on shares of uniQure in a research report on Monday, March 2nd. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $15.00 to $60.00 in a report on Monday. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $11.00 to $35.00 in a report on Monday. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $35.00 price objective on shares of uniQure in a research report on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

uniQure Stock Performance

Shares of QURE opened at $17.56 on Thursday. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -5.09 and a beta of 0.73. uniQure N.V. has a 12 month low of $7.76 and a 12 month high of $71.50. The firm has a fifty day simple moving average of $21.67 and a 200 day simple moving average of $29.58. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. Research analysts forecast that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Several analyst upgrades and bullish reports have pushed optimism around the company’s pipeline — Mizuho upgraded QURE to “outperform” with a $35 target (up from $12), and other firms (RBC, Wells Fargo, Chardan) have issued more favorable notes recently, supporting a rebound narrative for the stock. Mizuho Upgrade
• Positive Sentiment: H.C. Wainwright reaffirmed a Buy rating and kept a $70 price target, citing regulatory shifts and AMT‑130 outlook as catalysts that could drive long-term upside. H.C. Wainwright Note
• Neutral Sentiment: Shares previously spiked (~26% reported) on an FDA leadership shakeup that some investors hoped would favor uniQure’s Huntington’s therapy pathway — a short-term momentum event that may have already priced in expectations. MSN Coverage
• Negative Sentiment: Regulatory risk intensified after reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” or “manipulated” data around the failed AMT‑130 program — a serious development that raises oversight, approval, and credibility concerns. FDA Allegation Report
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors for securities‑fraud class actions tied to uniQure’s FDA delays and share decline, creating legal overhang, potential liabilities, and continued headline risk that can pressure the stock. Kessler Topaz Filing
• Negative Sentiment: Short interest jumped significantly in February (over 17% increase), now representing ~21% of float — a condition that can amplify downside on negative news and reflects elevated bearish positioning.

Insider Buying and Selling at uniQure

In other uniQure news, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director owned 32,342 shares of the company’s stock, valued at $796,260.04. The trade was a 44.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christian Klemt sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the sale, the chief financial officer owned 226,581 shares in the company, valued at approximately $2,052,823.86. This represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,399 shares of company stock valued at $1,527,645 in the last ninety days. Insiders own 4.79% of the company’s stock.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.